Drugs in MeSH Category Provitamins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	SOLATENE	beta carotene	CAPSULE;ORAL	017589-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Provitamins

Last updated: June 19, 2026

Executive summary: The NLM MeSH class “Provitamins” is a category-level scope that aggregates multiple actives and dosage forms, each with distinct patent estates and exclusivity timelines. A complete, decision-grade patent landscape requires drug-level identification of (1) specific provitamin actives, (2) their FDA-approved products and strengths, and (3) the Orange Book/NDA-BLA records tied to each product. Without the specific provitamin drug list and the associated FDA application numbers or NLM-to-Drug mappings, a complete patent landscape cannot be produced with integrity.

What drugs are classified as “provitamins” in MeSH and how does that affect patent landscaping?

Featured answer: MeSH “Provitamins” is a medical subject heading used for indexing, not a single regulatory product class. Patent coverage and exclusivity run at the individual drug-product level, so MeSH category tagging alone does not determine a unified patent estate.

How MeSH category structure changes how patents should be analyzed

Provitamins span chemically and pharmacologically distinct molecules used for vitamin precursor biology and supplementation. Patent landscapes in this area typically break down along three axes:

• Active ingredient family (e.g., vitamin A precursors versus vitamin D precursors versus provitamin carotenoids)
• Regulatory identity (Rx vs OTC, NDA vs ANDA, supplements marketed without FDA approvals)
• Formulation and delivery system (softgels, emulsions, stabilized blends, water-miscible forms)

What investors and litigators need at the start

A defensible landscape requires:

• Drug-product mapping to FDA label and Orange Book listing
• Identification of the application (NDA/ANDA/BLA number)
• Extraction of all listed patent numbers and their expiration dates
• Mapping to Paragraph IV filings and any litigation/settlement that impacts generic timelines

Which patents protect provitamins: API composition, formulation, method-of-use, or manufacturing?

Featured answer: For most vitamin-provitamin products, the dominant patent risk typically sits in formulation, stability, and manufacturing/process patents, with composition-of-matter sometimes present but often older and closer to expiration.

Patent types commonly present in provitamins

• Composition of matter (API/process chemistry): Often originates from earlier discovery and may be substantially expired for long-established vitamins/provitamins.
• Formulation and stability: Protects stabilized blends, antioxidant packages, capsule matrices, emulsions, and bioavailability improvements.
• Method of use: Protects specific dosing regimens for defined subpopulations or clinical outcomes (less common for pure supplementation products, more common when used in therapeutic contexts).
• Manufacturing and scale-up: Protects granulation, moisture control, sterilization, encapsulation approaches, or controlled-release designs.

How to interpret “weak composition, strong formulation” outcomes

When the API estate is old, generic entry can be blocked by:

• Listed formulation patents
• Listed manufacturing patents that prevent “carve-out” design changes
• Listed method-of-use patents if the generic’s label would trigger infringement

When does provitamin exclusivity end and what drives generic entry timing?

Featured answer: Generic entry is usually driven by the earlier of (1) Orange Book patent expiration and (2) relevant FDA exclusivity or blocking due to Paragraph IV litigation timing under Hatch-Waxman.

Timing drivers that matter for provitamins

1. Patent expiration dates listed in the Orange Book (earliest-to-expire is the key)
2. Regulatory exclusivity
   • 5-year New Chemical Entity (NCE) exclusivity applies only when criteria are met for the specific product and approval history
   • 3-year exclusivity may apply for changes to approved products (new formulation, new indication, etc.)
3. 30-month stay triggered by Paragraph IV notice letters, if a qualifying suit is brought
4. Court-ordered injunctions or settlement terms that accelerate or delay launch

Practical launch calendar mechanics

For vitamin/provitamin products, there are frequent scenarios:

• Patents expire with no active litigation: generic or retailer private-label reformulates or launches when label and manufacturing requirements are satisfied.
• Late-arising formulation/process patents: brand may extend the runway through secondary patents listed after initial approval.
• Settlements affecting ANDA effective dates: an ANDA may be ready but blocked contractually or by injunction until a stipulated date.

How many patents cover provitamins and which assignees dominate the estate?

Featured answer: The number of patents per provitamin product varies widely by active ingredient, but category-level indexing does not yield a reliable count. Dominant assignees typically map to brand holders of the leading NDA and their line extensions.

What “patent density” usually looks like by product lifecycle stage

• Newer therapeutic provitamins or specialized delivery forms: higher count of formulation and method patents.
• Legacy supplementation products: fewer active patents; remaining estates concentrate in stabilizing excipient systems and manufacturing.

Dominant assignee patterns (how to structure the analysis)

A litigation-ready table should include:

• Assignee/patent holder
• Patent number
• Claims scope (API vs formulation vs method vs process)
• Listed expiry date
• Expiration earliest among asserted patents
• Country coverage (US-only vs PCT-family expansion)

What is the Orange Book status of provitamin drugs and how many are listed as “drug products with patents”?

Featured answer: Orange Book status and patent listing are product-specific. MeSH “provitamins” does not identify which provitamin products have Orange Book listings, nor does it indicate whether products are marketed as supplements outside the FDA approval framework.

Orange Book fields that determine freedom-to-operate

A standard Orange Book extraction should capture:

• Product name, dosage form, route
• NDA number
• Listed patents and patent types
• Patent expiration dates
• Patent submission type (new drug submission, change in site, formulation change, etc.)

Generic risk classification used in practice

• Low risk: no unexpired patents in Orange Book for the relevant strengths/dosage forms
• Medium risk: unexpired formulation patents with potential for non-infringing design-around
• High risk: multiple unexpired patents across API/formulation/method and evidence of active litigation or enforcement

Which companies are challenging provitamin patents via Paragraph IV and what does that imply for settlement?

Featured answer: Paragraph IV challenges are determined at the NDA product level. A MeSH class view cannot identify challengers without the underlying product list and Orange Book patent entries.

What to track for each provitamin NDA

• ANDA filer name(s)
• Notice date
• Suit filing date
• Patents asserted by brand holder
• Court jurisdiction and docket status
• Settlement effective date and permitted launch date

Settlement terms that most affect market dynamics

Common settlement outcomes that shift market share:

• Staggered launch by strength and dosage form
• License for manufacturing/process with design constraints
• “Copy vs carve-out” changes that preserve infringement non-willfulness but limit generic label
• Exclusivity carve-outs to protect specific indications

How do patent estates for provitamins compare with competing vitamin precursor products?

Featured answer: Patent estates in provitamins should be benchmarked against adjacent vitamin classes using the same method: Orange Book patent mapping at product-strength level, then counting unexpired patents and active litigation.

Comparison framework

For each paired active (or delivery platform), compare:

• Earliest unexpired US patent expiration
• Count of listed patents by type (composition, formulation, method, process)
• Presence of active Paragraph IV litigation
• Whether brand has multiple strengths listed with distinct patent coverage
• Manufacturing constraints that make “label-only” workarounds insufficient

What formulations are protected for provitamins and what are the typical generic design-around routes?

Featured answer: Formulation and stability patents are commonly the main barrier. Generic design-around typically focuses on reformulation chemistry, excipient selection, capsule fill/matrix changes, or modified dissolution profiles.

Typical protected elements in provitamin products

• Antioxidant stabilization systems
• Moisture/oxygen barrier encapsulation
• Controlled-release or enhanced bioavailability matrices
• Water-miscible emulsions and surfactant systems
• Particle size and dispersion control affecting dissolution

Generic routes that can still trigger infringement

• Matching “functional” characteristics while altering disclosed composition may still infringe if claims cover a broader functional range.
• Manufacturing process claims can block approval even if final formulation is altered.

What patent litigation affects provitamin products in the US?

Featured answer: Litigation is product-specific and must be sourced from dockets tied to the NDA patents asserted. Category-level coverage is not legally actionable.

Litigation intelligence workflow used for US market assessments

• Identify brand NDA(s) under “provitamins”
• Extract Orange Book patents
• Search for Paragraph IV notices and suit filings for those patents
• Map settlement terms to expected launch dates
• Track any injunction or stipulation impacting FDA approval timing

How does FDA regulatory status shape commercialization of provitamins?

Featured answer: FDA approval status determines whether the competitive path runs through ANDA (generic) versus supplement/OTC routes that are outside Hatch-Waxman exclusivity/patent linkage.

Regulatory pathways that change market dynamics

• NDA-approved Rx supplements: Hatch-Waxman patent linkage applies if listed in Orange Book
• OTC/ dietary supplements: patent linkage framework may not apply, but formulation IP may still matter commercially
• 501(b)(2) and 505(b)(2) routes: may allow “reliance” and can reshape patent strategy around listed patents

Label and strength matters

For provitamins, different strengths can have distinct patent coverage and different patent filing histories, changing generic timing by product presentation.

What generic entry risks exist for provitamins and how can brands mitigate them?

Featured answer: Generic entry risk is highest where brands rely on late-listed formulation/process patents and where ANDA challengers can produce non-infringing bioequivalent versions without violating process claims.

Risk-reduction levers used in this category

• Tight linkage of brand claims to excipient systems and stabilization methods
• Continuation patenting around manufacturing controls and shelf-life stability protocols
• Enforcement targeting the specific dosage form and strength with the strongest claim coverage
• Settlement structures that allow delayed launch or licensed entry with constraints

Key Takeaways

• MeSH “Provitamins” is a category index, not a single patent estate. US exclusivity and patent protection must be mapped to specific FDA-approved provitamin products and strengths.
• Patent risk in provitamins is typically concentrated in formulation and manufacturing/stability patents, with composition-of-matter more likely to be older.
• Generic launch timing is driven by Orange Book patent expiration, FDA exclusivity (when applicable), and Paragraph IV litigation/settlement effects, all at the individual NDA product level.
• A decision-grade landscape requires a drug-by-drug Orange Book and litigation mapping workflow; category-level framing cannot support actionable patent counts, expiration timelines, or risk rankings.

FAQs

1. How do I determine which provitamin products are Orange Book-listed versus marketed as dietary supplements?
2. What patent types most often block generic ANDAs for vitamin or provitamin formulations in the US?
3. How does a Paragraph IV notice date translate into a practical expected generic launch window for provitamins?
4. Do provitamin method-of-use patents commonly constrain generics, or is the risk mostly formulation and process?
5. What settlement terms most frequently delay ANDA launches for branded supplementation products?

References

1. U.S. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA, Hatch-Waxman Act overview and exclusivity framework (general). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
3. NLM MeSH Browser, “Provitamins” (category definition). https://meshb.nlm.nih.gov/